Compania BioNTech, unul dintre pionerii vaccinurilor anti-Covid-19, se pregătește să închidă trei fabrici în Germania - Economica.net

BioNTech plans to close three factories in Germany, risking 1,800 jobs due to overcapacity and cost-cutting measures. The company aims to save up to 500 million euros annually, reallocating funds for cancer drug research and development. The closures will affect facilities in Idar-Oberstein, Marburg, and Tübingen unless buyers are found. Despite significant earnings from Covid-19 vaccines, BioNTech has struggled to launch new products. The company also announced a new CEO, Guido Oelkers, set to take over by February 2027, as co-founder Ugur Sahin prepares to leave for a new venture focused on mRNA technology. BioNTech reported a billion-euro loss last year, anticipating revenues of 2 to 2.3 billion euros in 2026, amid declining vaccine sales.